De Novo device
Tangible Boost
Tangible Science, Inc. · Hydrophilic Re-Coating Solution (QMM, Class II) · First FDA decision Sep 24, 2020, newest Sep 24, 2020Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
2
Naming "Tangible Boost"
MAUDE reports
1
Brand "Tangible Boost", since 2015
PubMed studies
0
Mentioning "Tangible Boost"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Tangible Boost
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Tangible BoostNew device typeDe Novo
DEN200002 · Decided Sep 24, 2020 · 255 days after receipt
Device type: Hydrophilic Re-Coating Solution (QMM) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Tangible Boost", any status and sponsor, newest update first.
Tangible ScienceNot on our public-company list
NCT04313725 · 28 participants · Start Feb 24, 2020 · Primary completion Jun 21, 2023
Device: Tangible Boost · For: Stevens-Johnson Syndrome; Graft Versus Host Disease in Eye; Sjogren's Syndrome and 1 more
Sites: Needham, Massachusetts
Tangible ScienceNot on our public-company list
NCT03073148 · 35 participants · Start Feb 24, 2017 · Primary completion Feb 13, 2019
Device: Tangible Boost · For: Contact Lens Solution
Sites: Houston, Texas
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Tangible Boost", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code QMM
1 reports: 1 malfunction, 0 injury, 0 death
Newest reports for this brand
- TANGIBLE BOOSTMalfunction
MW5170501 · Received May 16, 2025 · Event dated May 13, 2025
Device type: Hydrophilic Re-Coating Solution (QMM)
Device problem as coded: Expiration Date Error
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Tangible Boost"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.